Room to Run, the Race for a COVID-19 Antibody Drug, and the Most Underappreciated Risk
Another rally on Wall Street and two strategists both say there’s more room to run…where they’re finding opportunities. The CEO of AbCellera joins to discuss the company’s partnership with Eli Lilly in the race for a COVID-19 antibody drug. And two policy strategists weigh in one of the biggest and most underappreciated risks for the market right now. Plus, a ‘cool’ trade for the summer.
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Another rally on Wall Street and two strategists both say there’s more room to run…where they’re finding opportunities.
The CEO of AbCellera joins to discuss the company’s partnership with Eli Lilly in the race for a COVID-19 antibody drug.
And two policy strategists weigh in one of the biggest and most underappreciated risks for the market right now.
Plus, a ‘cool’ trade for the summer.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.